

Appendix 1 - List of amendments requiring MHRA authorisation only

New toxicological or pharmacological data or new interpretation of toxicological to pharmacological data of relevance for the investigator
Changes to the reference safety information for the development safety update report (DSUR)
Changes to the investigational medicinal product dossier
Reduction in the Sponsor's planned level of monitoring for the trial